{
    "clinical_study": {
        "@rank": "79046", 
        "arm_group": {
            "arm_group_label": "Study group", 
            "arm_group_type": "Experimental", 
            "description": "Amlodipine/Valsartan Single-Pill Combination"
        }, 
        "brief_summary": {
            "textblock": "The antihypertensive effect of Amlodipine/Valsartan combination has been evaluated in\n      worldwide populations including Asian patients. The study primarily aims to evaluate the\n      effectiveness of Amlodipine/Valsartan combination in patients with essential hypertension in\n      Taiwan using a prospective, open-label, non-randomized approach.\n\n      The study also wants to investigate the safety of Amlodipine/Valsartan combination during\n      the 6-week treatment period."
        }, 
        "brief_title": "PMS Study of Amlodipine/Valsartan for the Treatment of Hypertension", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Essential Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who are 20-80 years of age\n\n          -  Patients with essential hypertension (90 mmHg \u2264 DBP \u2264 110 mmHg and/or 140 mmHg \u2264 SBP\n             \u2264 180 mmHg) whose BP is not adequately controlled with amlodipine (or another CCB)\n             alone or with valsartan (or another ARB) alone, or with any antihypertensive\n             monotherapy.\n\n          -  Agree to and are able to follow the study procedures\n\n          -  Understand the nature of the study, and have signed informed consent forms\n\n        Exclusion Criteria:\n\n          -  Patients with any of the following conditions:\n\n               1. Malignant (or history of malignant) hypertension\n\n               2. Secondary hypertension\n\n               3. Severe hypertension (mean sitting DBP \u2265 110 mmHg and/or mean sitting SBP \u2265 180\n                  mmHg)\n\n               4. A history of hypertensive encephalopathy or cerebrovascular accident\n\n               5. Cerebrovascular accident, myocardial infraction within 3 months, or any type of\n                  revascularization\n\n               6. New York Heart Association class III -IV congestive heart failure\n\n               7. Second- or third-degree heart block\n\n               8. Angina pectoris\n\n               9. Significant arrhythmia or valvular heart disease\n\n              10. Significant pancreatic, hepatic, or renal disease\n\n              11. Diabetes requiring insulin treatment or poorly controlled type 2 diabetes\n\n          -  Patients with known contraindication or a history of allergy to CCBs or ARBs.\n\n          -  Female patients who are pregnant or lactating.\n\n          -  Male or female patients of child-bearing potential who do not agree to use an\n             effective method of contraception during the study\n\n          -  Patients is currently participating in any other clinical trial within 30 days"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02058446", 
            "org_study_id": "TSHAM1301"
        }, 
        "intervention": {
            "arm_group_label": "Study group", 
            "description": "Amlodipine/Valsartan: 5 mg/80 mg", 
            "intervention_name": "Amlodipine/Valsartan", 
            "intervention_type": "Drug", 
            "other_name": "Am-Daiwen\u00ae"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Amlodipine", 
                "Valsartan", 
                "Amlodipine, valsartan drug combination"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 6, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Taichung", 
                    "country": "Taiwan", 
                    "zip": "40705"
                }, 
                "name": "Taichung Veterans General Hospital"
            }
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label, Postmarketing Study of Amlodipine/Valsartan Single-Pill Combination for the Treatment of Hypertension", 
        "overall_official": {
            "affiliation": "Taichung Veterans General Hospital", 
            "last_name": "Kuo-Yang Wang, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Taiwan : Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To evaluate the change from baseline in office SBP measurements by cuff assessments at the end of the 6-week study period.", 
            "safety_issue": "No", 
            "time_frame": "6 weeks from baseline"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02058446"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "To evaluate  the change from baseline in office DBP measurements by cuff assessments after 6 weeks of treatment", 
                "safety_issue": "No", 
                "time_frame": "6 weeks from baseline"
            }, 
            {
                "measure": "To evaluate the percentage of subjects who achieve BP goal as measured by cuff assessments (<140/90 mmHg) after 6 weeks of treatment", 
                "safety_issue": "No", 
                "time_frame": "6 weeks from baseline"
            }
        ], 
        "source": "TSH Biopharm Corporation Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "TSH Biopharm Corporation Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}